Article

Multiple Sclerosis Research Findings Top SPT Week in Review

Author(s):

Top news of the week from Specialty Pharmacy Times.

5. Investigational HIV Therapy Further Demonstrates Efficacy in Phase 3 Trial

Study evaluates doravirine once daily compared with ritonavir-boosted darunavir, each taken in combination with other antiretroviral agents. Read more.

4. FDA Approves Extended-Release Injectable Suspension for Schizophrenia

Officials with the FDA have approved risperidone (Perseris, Indivior) for extended-release injectable suspension for the treatment of schizophrenia in adults. Read more.

3. FDA Grants Fast Track Designation to Hepatitis B Drug

The FDA recently granted Fast Track designation to Assembly Biosciences, Inc’s novel treatment for patients with chronic hepatitis B virus (HBV) infection. Read more.

2. Use of Truvada for HIV Prevention Associated with Decline in New US Diagnoses

Nationwide analysis of Truvada for pre-exposure prophylaxis use finds uptake associated with significant decrease in new HIV infections. Read more.

1. Research Sheds Light on New Drug Targets for Regenerative MS Therapies

Study finds that several multiple sclerosis drug candidates inhibit the same enzyme to stimulate myelin regeneration. Read more.

Related Videos
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
October is American Pharmacists Month.
smiling indian male doctor or pharmacist in white coat with stethoscope and clipboard over drugstore background
Efficient healthcare supply chain management ensures timely delivery of medical supplies and medications
Alzheimer and dementia clock drawing cognitive test -- Image credit: Jovana Milanko/Stocksy | stock.adobe.com
Pharmacy Benefit Manager Transparency | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Benefit Manager Regulation | Image Credit: Tyler Olson - stock.adobe.com
Caregiver holding elderly man's hand -- Image credit: Chinnapong | stock.adobe.com
Health care worker looking at MRI scans of dementia -- Image credit: Atthapon | stock.adobe.com